AbbVie Inc. is a North Chicago-based biopharmaceutical company created from Abbott Laboratories in 2013. AbbVie reported $61.160 billion in FY2025 net revenue, led by Skyrizi, Rinvoq, Humira, Botox, neuroscience, oncology, and aesthetics, and is led by chairman and CEO Robert A. Michael.
AbbVie Inc.: Key Facts
| Company Name | AbbVie Inc. |
|---|---|
| Founded | 2013 |
| Origin | Spin-off from Abbott Laboratories |
| Founding CEO | Richard A. Gonzalez |
| Headquarters | North Chicago, Illinois, United States |
| Industry | Biopharmaceuticals |
| CEO | Robert A. Michael |
| Employees | Approximately 57,000 |
| Revenue (FY2025) | $61.160 billion |
| Market Cap | Approximately $451.5 billion as of July 20, 2026 |
| Website | abbvie.com |
- Revenue sourced to AbbVie FY2025 results and annual reporting materials
- Regulatory-risk notes checked against CMS and FDA sources
- Leadership and employee count checked against AbbVie leadership profile
- For informational purposes only - not financial advice
AbbVie is one of the clearest examples of a modern pharma company built around a patent-cliff problem. The company was created when Abbott Laboratories separated its research-based pharmaceutical business in 2013, giving AbbVie control of Humira and a focused drug-development strategy. Humira became the cash engine that funded dividends, acquisitions, and pipeline work, but its U.S. biosimilar competition forced AbbVie to prove it could grow without relying on one historic blockbuster.
By FY2025, AbbVie had crossed that test better than many investors expected. The company reported $61.160 billion in net revenue, with immunology revenue of $30.406 billion and fast growth from Skyrizi and Rinvoq. Those two medicines together generated $25.866 billion in FY2025, more than replacing much of Humira's decline and giving AbbVie a new center of gravity in inflammatory disease.
What Does AbbVie Do?
AbbVie discovers, develops, manufactures, and sells specialty medicines across immunology, neuroscience, oncology, aesthetics, eye care, and other therapeutic areas. Its best-known products include Skyrizi, Rinvoq, Humira, Botox Therapeutic, Botox Cosmetic, Vraylar, Imbruvica, Venclexta, Elahere, Ubrelvy, and Qulipta.
How Does AbbVie Make Money?
AbbVie makes money from global sales of branded medicines and aesthetics products. The largest segment is immunology, where Skyrizi, Rinvoq, and Humira generated $30.406 billion in FY2025 revenue. Neuroscience contributed $10.767 billion, oncology contributed $6.655 billion, and aesthetics contributed $4.860 billion.
The business works because successful patented medicines can generate high revenue for many years, but that same model creates patent-expiration risk. AbbVie's strategy is to use the cash flow from mature drugs to fund new indications, pipeline development, dividends, debt reduction, and targeted acquisitions.
AbbVie Revenue and Financials
AbbVie reported FY2025 net revenue of $61.160 billion, up 8.6% on a reported basis. Q1 2026 revenue was $15.002 billion, up 12.4% on a reported basis, with Skyrizi at $4.483 billion, Rinvoq at $2.119 billion, and Humira at $688 million for the quarter.
The most important financial trend is the shift from Humira to Skyrizi and Rinvoq. Humira generated $4.540 billion in FY2025 after years of biosimilar pressure, while Skyrizi reached $17.562 billion and Rinvoq reached $8.304 billion.
AbbVie History
AbbVie began trading independently in 2013 after Abbott Laboratories split its research-based pharmaceutical business from its diversified healthcare operations. Richard A. Gonzalez became the founding CEO and led the company through the Humira peak, the Pharmacyclics acquisition, the Allergan acquisition, the U.S. Humira loss of exclusivity, and the early Skyrizi/Rinvoq growth phase.
The largest transformation came in 2020, when AbbVie completed the roughly $63 billion Allergan acquisition. That deal added Botox, Juvederm, Vraylar, Ubrelvy, Qulipta, and a global aesthetics business that made AbbVie less dependent on pure immunology revenue.
AbbVie Acquisitions
AbbVie's key acquisitions include Pharmacyclics in 2015, Allergan in 2020, ImmunoGen in 2024, and Cerevel Therapeutics in 2024. Pharmacyclics strengthened oncology through Imbruvica, Allergan added Botox and aesthetics, ImmunoGen added Elahere, and Cerevel added neuroscience pipeline depth around emraclidine.
AbbVie CEO and Leadership
Robert A. Michael is AbbVie's chairman and chief executive officer. He became CEO in 2024 after Richard A. Gonzalez retired from the CEO role. Michael previously served as president, chief operating officer, chief financial officer, and a senior architect of AbbVie's business development and post-Humira strategy.
AbbVie Competitors
AbbVie competes with Johnson & Johnson, Eli Lilly, Pfizer, Merck, Amgen, Bristol Myers Squibb, Regeneron, Roche, Novartis, Sanofi, AstraZeneca, and other global biopharmaceutical companies. Its most direct battlegrounds are immunology, oncology, neuroscience, aesthetics, and specialty drug pricing.
AbbVie FAQ
What is AbbVie known for?
AbbVie is known for immunology medicines such as Skyrizi, Rinvoq, and Humira, plus Botox, Vraylar, oncology drugs, and specialty biopharmaceutical research.
What was AbbVie revenue in FY2025?
AbbVie reported $61.160 billion in FY2025 net revenue, up 8.6% on a reported basis from FY2024.
Who is the CEO of AbbVie?
Robert A. Michael is AbbVie's chairman and chief executive officer. He became CEO in 2024 after Richard A. Gonzalez retired from the CEO role.
Who founded AbbVie?
AbbVie was created as a 2013 spin-off from Abbott Laboratories. Richard A. Gonzalez led the new public company as its founding CEO.
How does AbbVie make money?
AbbVie makes money by selling patented and specialty medicines in immunology, neuroscience, oncology, aesthetics, eye care, and other therapeutic areas.
What are AbbVie's biggest drugs?
AbbVie's largest FY2025 growth drugs included Skyrizi at $17.562 billion and Rinvoq at $8.304 billion, while Humira remained meaningful at $4.540 billion.
How many employees does AbbVie have?
AbbVie says it employs approximately 57,000 people worldwide.
Where is AbbVie headquartered?
AbbVie is headquartered in North Chicago, Illinois, United States.
Who are AbbVie's main competitors?
AbbVie competes with Johnson & Johnson, Eli Lilly, Pfizer, Merck, Amgen, Bristol Myers Squibb, Regeneron, Roche, Novartis, and other biopharma companies.
What is AbbVie's biggest strategic risk?
AbbVie's biggest risk is replacing declining Humira revenue while defending Skyrizi, Rinvoq, Botox, oncology, and neuroscience growth against competitors and pricing pressure.
